The Market Herald: Rakovina Therapeutics (TSXV:RKV) partners with St. Baldrick’s Foundation



"Rakovina (RKV) is partnering with St. Baldrick's Foundation to develop treatments for childhood bone cancer. It was selected to join a three-year C$1,297,000 research program funded by St. Baldrick's Martha's BEST Grant for All. The grant focuses on treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults. Dr. Mads Daugaard, Co-founder, President, and CSO sat down with Dave Jackson to discuss Rakovina's partnership with St. Baldrick's Foundation."


For the full interview with Dr. Mads Daugaard

and to learn more about Rakovina's recent partnership, click here.


SOURCE

Recent Posts

See All